-
Intestinal Stretch, Obesity, and Weight Loss
2026-08-27
The reference study shows that intestinal stretch is an acute regulator of food intake and glucose tolerance that operates independently of classical GLP-1 signaling. It further demonstrates that obesity weakens this gut–brain response, whereas dietary or surgical weight loss restores it, refining how researchers interpret gastrointestinal mechanosensation in metabolic disease.
-
Dynasore: Practical Dynamin Inhibition Guide
2026-08-26
Dynasore is a cell-permeable dynamin GTPase inhibitor for experimentally perturbing dynamin-dependent endocytosis, vesicle trafficking, and related cellular readouts. This guide explains how to prepare and control Dynasore assays, while clarifying that it should not be treated as a pathway-exclusive probe, therapeutic, or substitute for orthogonal validation.
-
Disulfiram: Proteasome and Pyroptosis Research Guide
2026-08-26
Disulfiram is a dopamine β-hydroxylase inhibitor and aldehyde dehydrogenase inhibitor with established alcohol-dependence use and expanding preclinical roles in proteasome, cancer, and inflammasome research. Copper-associated proteasome inhibition and GSDMD-directed pyroptosis modulation are distinct experimental mechanisms that require separate controls.
-
In Vitro Embryonic Dormancy Through mTOR Inhibition
2026-08-25
The Nature Protocols paper converts pharmacologically induced mTOR inhibition into a detailed, reversible in vitro workflow for placing mouse blastocysts, human blastoids, and pluripotent stem cells into a diapause-like state. Its main practical contribution is a noninvasive and scalable framework for studying dormancy, reactivation, and developmental competence across mammalian models.
-
Dantrolene sodium salt: RyR Workflows
2026-08-25
Dantrolene sodium salt provides a reversible way to interrogate ryanodine receptor-driven calcium release in cardiomyocyte, pancreatitis, and disease-modeling workflows. This guide pairs calcium imaging and viability controls with an exploratory CRISPR repair-outcome assay, clearly separating established RyR biology from emerging cross-domain questions.
-
WEHI-539: A Selective BCL-XL Inhibitor Workflow
2026-08-24
WEHI-539 enables selective interrogation of BCL-XL-dependent survival, mitochondrial apoptosis, and resistance states without the interpretive ambiguity of broad BCL-2-family perturbation. This workflow connects formulation control, mechanistic apoptosis readouts, cancer stem cell sensitization, and MCL-1-focused combination studies.
-
GSK2606414 PERK Inhibitor: Workflow Guide
2026-08-24
GSK2606414 provides a precise way to test whether PERK signaling drives ER-stress responses, lipid injury, cell death, or tumor adaptation. This workflow guide translates a TMAO–NAFLD study into practical dose-finding, pathway-validation, troubleshooting, and cross-model assay strategies.
-
Paroxetine Mesylate Research Workflows
2026-08-23
Paroxetine Mesylate supports more than conventional serotonergic studies: it can connect SERT pharmacology with kinase-focused colorectal cancer assays. This guide converts that multi-target profile into practical workflows, controls, and troubleshooting decisions for translational researchers.
-
DAMGO and the Circuit Logic of Opioid Pain
2026-08-22
DAMGO is more than a selective µ-opioid receptor agonist: it is a precision probe for connecting receptor activation with tissue responses, brain-to-spinal circuits, mechanical hypersensitivity, and translational risk in chronic pain research.
-
PYR-41: Designing Better Ubiquitination Assays
2026-08-21
PYR-41, an inhibitor of Ubiquitin-Activating Enzyme E1, can reveal how ubiquitination controls inflammatory signaling. This article translates recent ESCC B-cell findings into a practical assay strategy while defining the compound’s selectivity and interpretation limits.
-
Camostat Mesilate: From Protease Biology to Translation
2026-08-20
Camostat Mesilate offers a tractable way to interrogate ENaC-linked protease biology, plasmin–TGF-β signaling, and fibrosis. When viewed alongside structure-guided SARS-CoV-2 proteomimetics, it also illustrates how translational teams can compare enzyme modulation with protein–protein interaction blockade without confusing distinct mechanisms or assay outcomes.
-
X-Gal Beyond Screening: A Translational Strategy
2026-08-20
X-Gal remains a powerful visual reporter for molecular cloning, but its greatest value emerges when blue-white colony screening is treated as the first decision point in a broader validation strategy. This article connects the chemistry of 5-bromo-4-chloro-indolyl-β-D-galactopyranoside with translational experimental design and the emerging biology of iRhom2-dependent sensory signaling.
-
DAMGO in µ-Opioid Receptor Signaling
2026-08-19
DAMGO provides a selective way to activate µ-opioid receptors in membrane assays, ex vivo tissues, and anatomically targeted pain studies. Its value extends beyond analgesia testing: focal DAMGO stimulation can help distinguish receptor signaling from the brain-to-spinal circuits that drive mechanical hypersensitivity and tolerance.
-
Candida EVs Restrain Hyphae Through Nrg1
2026-08-19
The reference study shows that accumulated Candida albicans extracellular vesicles suppress yeast-to-hypha transition by increasing NRG1 transcription through an SKO1-associated regulatory circuit. Genetic validation and a candidemia model connect this vesicle-mediated transcriptional response with reduced fungal virulence, while also identifying EV cargo proteins as important effectors.
-
Brain-to-Spinal Circuits in Mechanical Allodynia
2026-08-18
This Cell Reports study identifies a contralateral lPBN Oprm1–dmH Pdyn–spinal dorsal horn pathway that regulates whether mechanical allodynia becomes bilateral and how long it persists. Its combination of circuit-specific silencing, activation, peptide deletion, and spinal receptor blockade provides a mechanistic framework for studying descending control of chronic pain.